Editor’s note: Find the latest COVID-19 news and guidance in Medscape’s Coronavirus Resource Center. Eli Lilly announced it will halt its ACTIV-3 trial evaluating the antibody bamlanivimab in combination with remdesivir for people hospitalized with COVID-19, after new evidence regarding efficacy emerged. The new data from the National Institutes of […]
Tuesday, Oct 3, 2023
Breaking News
- Home
- Lilly